Currently, it has been proven that the combination therapy of oral hypoglycemic agents and insulin can alleviate insulin resistance, reduce insulin dosage, avoid iatrogenic hyperinsulinemia, reduce the incidence of hypoglycemia, and achieve better glycemic control. The gene discussed is INS; the disease is Insulin resistance.